Article Contents ::
- 1 The Brand Name KAMIPRIL-5 Has Generic Salt :: Ramipril
- 2 KAMIPRIL-5 Is From Company Kamron Priced :: Rs. 34
- 3 KAMIPRIL-5 have Ramipril is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
- 5 Disclaimer ::
The Brand Name KAMIPRIL-5 Has Generic Salt :: Ramipril
KAMIPRIL-5 Is From Company Kamron Priced :: Rs. 34
KAMIPRIL-5 have Ramipril is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Congestive heart failure, MI, HTN, CV events, Stroke
Drug Dose ::
Adult: PO HTN Initial: 1.25 mg at bedtime. Maintenance: 2.5-5 mg/day as a single dose, up to 10 mg/day if needed. Heart failure Initial: 1.25 mg once daily. Max: 10 mg/day. MI Start 3-10 days after infarction. Initial: 2.5 mg twice daily after 2 days, then 5 mg twice daily. Maintenance: 2.5-5 mg twice daily. Prophylaxis of CV events in high-risk patients Initial: 2.5 mg once daily for 1 wk, then increased if tolerated to 5 mg once daily for 3 wk, then maintenance: 10 mg once daily. Renal impairment: CrCl (ml/min) 10-30 Initially, 1.25 mg/day. Max: 5 mg/day. 30-60 Not necessary to adjust the initial dose. Max: 5 mg/day. Hepatic impairment: Max: 2.5 mg/day.
Hypersensitivity, bilateral renal artery stenosis, or a single kidney with unilateral renal artery stenosis. Aortic stenosis or outflow tract obstruction. Pregnancy and lactation.
Drug Precautions ::
Renal impairment, hypovolaemia, hyperkalaemia, valvular stenosis; before, during or immediately after anaesthesia. Severe resistant hypertension, elderly, peripheral vascular disease or generalised atherosclerosis. Monitor renal function before and during treatment. Use with caution in patients with history of idiopathic or hereditary angioedema. Regular monitoring of WBC in patients with vascular collagen disorders is recommended.
Drug Side Effects ::
Nausea, vomiting, diarrhoea, dizziness, fatigue, headache, abdominal pain, cough. Rarely symptomatic hypotension. Angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions. Potentially Fatal: Severe hypotension and renal failure, angioedema.
Pregnancy category ::
Drug Mode of Action ::
Ramipril, a prodrug of ramiprilat, competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation thus producing a hypotensive effect and a beneficial effect in CHF.
Drug Interactions ::
May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements. Potentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment